Doxorubicin Activation and Its Effects on Leukaemia Cells
Author Information
Author(s): Kostrzewa-Nowak D, Paine M J I, Wolf C R, Tarasiuk J
Primary Institution: University of Szczecin
Hypothesis
The study aims to examine the role of reductive activation of doxorubicin by human liver NADPH cytochrome P450 reductase in increasing its cytotoxic activity against multidrug-resistant tumour cells.
Conclusion
The reductive activation of doxorubicin by CPR significantly increases its cytotoxic activity against both sensitive and multidrug-resistant leukaemia cells.
Supporting Evidence
- The presence of CPR catalysing only the redox cycling of DOX had no effect in increasing its cytotoxicity against sensitive and MDR tumour cells.
- An important increase in cytotoxic activity of DOX after its reductive conversion by CPR was observed against HL60 as well as HL60/VINC and HL60/DOX cells.
- IC50 values for DOX activated by CPR were significantly lower compared to nonactivated DOX.
Takeaway
This study shows that a special enzyme can make a cancer drug work better against tough cancer cells that usually resist treatment.
Methodology
The study involved incubating HL60 leukaemia cells and its multidrug-resistant sublines with doxorubicin and measuring the cytotoxic effects after treatment with NADPH and CPR.
Limitations
The study was conducted in vitro, and the clinical significance of the findings remains to be elucidated.
Participant Demographics
The study focused on human promyelocytic leukaemia HL60 cell line and its multidrug-resistant sublines.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website